2023-05-19 09:05:52 ET
- Hologic ( NASDAQ: HOLX ) said it had received U.S. FDA clearance for Panther Fusion SARS-CoV-2/Flu A/B/RSV assay
- The assay detects and differentiates major respiratory viruses including SARS-CoV-2, flu A, flu B, and RSV.
- The panther fusion system delivers initial results in approximately three hours, processing over 1,000 tests in 24 hours
- New RespDirect collection kit simplifies sample loading, saving time and reducing errors
- Project funded by U.S. Department of Health and Human Services
- Hologic shipped over 200M SARS-CoV-2 tests worldwide, strengthens position as a leading molecular diagnostic company
For further details see:
Hologic receives FDA clearance for Panther Fusion to test COVID-19